Markets

Decoy Therapeutics Announces Its Exploring Non-Dilutive Federal Grants, Public Health Collaborations To Support Preclinical, Clinical Development Of Biodefense Pipeline

Sep 22, 2026 · 07:35 AM ET· updated 1h ago

Decoy Therapeutics, Inc. (NASDAQ:DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™) to target major respiratory and high consequence viral threats, today announced a refined corporate

Why It Matters

Decoy Therapeutics is looking for free government money and partnerships instead of raising new investor cash. This could mean the company wants to save money while it tests new virus-fighting medicines.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

DCOY5.13

+2.57 (+100.47%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.